Lv11
10 积分 2023-12-15 加入
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
5小时前
待确认
Mantle-Cell Lymphoma
12天前
已完结
Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
12天前
已完结
Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
12天前
已关闭
First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
21天前
已完结
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE
2个月前
已完结
Real-World Treatment Patterns and Outcomes in Previously Untreated Mantle Cell Lymphoma: Findings From a Retrospective Study
2个月前
已关闭
Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China
2个月前
已完结
Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China
2个月前
已关闭
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
2个月前
已完结
皖公网安备34019202002308
